Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2184 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2184Thanks for sharingFelix B-August 9
2183More colour (review): epvantage.comMiljenko Zuanic-August 9
2182Is Roche making mistake(s)? Their bigger one was favoring PD-L1 instead PD1 (escMiljenko Zuanic-August 8
2181Did Sanofi made same mistake with Fasinumab, as it did with Eylea???? Well, 2Q bMiljenko Zuanic-August 4
2180I agree, they need second drug, not just 'scientifically sound" candidaMiljenko Zuanic-August 3
2179Motivated companies know where the next growth will come from. I believe I haveBiotech Jim-August 3
2178<Report results from Phase 3 asthma program in adults and adolescents> TMiljenko Zuanic-August 3
2177Next time/Q they should report 60-80 cents miss, so stock can rally few percent!Miljenko Zuanic-August 3
2176<I presume Miljenko is happy about sunset of SNY antibody collaboration> Miljenko Zuanic1August 3
2175I presume Miljenko is happy about sunset of SNY antibody collaboration: investorDewDiligence_on_SI-August 3
2174<It appears that Eylea will do well in 2Q...> $919 M is even bit better Miljenko Zuanic-August 3
2173Looking forward... Select Upcoming 2017 Milestones Programs Milestones Biotech Jim-August 3
2172Time will tell, their (and the rest of industries) ADC development has been a biFelix B-August 1
2171This plus Lilly's failure tighten up the market, curious if they can chip awFelix B-August 1
2170Sure they can, with anti-CD38 antibody (sanofi) for hematology and ant-LAG-3 (REMiljenko Zuanic-July 31
2169Stil early to tell but looks like PD1 rather than PD1-L is the better target. Felix B-July 31
2168AD market is not RA/psoriasis or cancer! Not even close. I mentioned early that Miljenko Zuanic-July 31
2167Have you seen the commercial-uptake chart for Eliquis? In early quarters, it looDewDiligence_on_SI-July 31
2166Difference between IL-6 and IL-6R (in RA): endpts.comMiljenko Zuanic-July 31
2165<Small consolation, but €26M recorded sales is about $30.6M (not $28.6M). RegMiljenko Zuanic-July 31
2164Small consolation, but €26M recorded sales is about $30.6M (not $28.6M). RegardsDewDiligence_on_SI-July 31
2163<One needs a telescope to see the $5B sales peak.> At this point even T.Miljenko Zuanic-July 31
2162Law360, New York (July 27, 2017, 7:51 PM EDT) -- The Federal Circuit said ThursdThe Ox-July 31
2161SNY Q2 results included $28.6M in Dupixent (dupilumab) sales, below expectationBiotech Jim-July 31
2160<In addition to tonight Sanofi 2Q report, I think that next week is importantMiljenko Zuanic-July 31
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.